The median time from the last dose of abelacimab to the procedure was 29 days, with 55.8% of procedures occurring within the monthly dosing interval. Periprocedural bleeding—ISTH major/clinically ...

In patients with atrial fibrillation (AFib) randomized to abelacimab vs. rivaroxaban, no statistically significant differences in bleeding risk were observed, suggesting that interruption of ...